よむ、つかう、まなぶ。
会議資料 (128 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000198856_00045.html |
| 出典情報 | 医療上の必要性の高い未承認薬・適応外薬検討会議（第67回 2／6）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
（公知申請への該当性に係る企業見解の様式）
要望番号；IV-140
4.
Penack O, Marchetti M, Ruutu T, et al. Prophylaxis and management of graft versus host disease
after stem-cell transplantation for haematological malignancies: updated consensus
recommendations of the European Society for Blood and Marrow Transplantation. Lancet
Haematol 2020;7(2):e157-67.
5.
Penack O, Marchetti M, Aljurf M, et al. Prophylaxis and management of graft-versus-host
disease after stem-cell transplantation for haematological malignancies: updated consensus
recommendations of the European Society for Blood and Marrow Transplantation. Lancet
Haematol 2024;11(2):e147-59.
6.
Storb R, Deeg HJ, Thomas ED, et al. Marrow transplantation for chronic myelocytic leukemia:
a controlled trial of cyclosporine versus methotrexate for prophylaxis of graft-versus-host
disease. Blood 1985;66(3):698-702.
7.
Ringdén O, Bäckman L, Lönnqvist B, et al. A randomized trial comparing use of cyclosporin
and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients
with haematological malignancies. Bone Marrow Transplant 1986;1(1):41-51.
8.
Storb R, Deeg HJ, Farewell V, et al. Marrow transplantation for severe aplastic anemia:
methotrexate alone compared with a combination of methotrexate and cyclosporine for
prevention of acute graft-versus-host disease. Blood 1986;68(1):119-25.
9.
Storb R, Deeg HJ, Fisher L, et al. Cyclosporine v methotrexate for graft-v-host disease
prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled
trials. Blood 1988;71(2):293-8.
10. Bäckman L, Ringdén O, Tollemar J, et al. An increased risk of relapse in cyclosporin-treated
compared with methotrexate-treated patients: long-term follow-up of a randomized trial. Bone
Marrow Transplant 1988;3(5):463-71.
11. Sullivan KM, Storb R, Buckner CD, et al. Graft-versus-host disease as adoptive immunotherapy
in patients with advanced hematologic neoplasms. N Engl J Med 1989;320(13):828-34.
12. Storb R, Deeg HJ, Pepe M, et al. Methotrexate and cyclosporine versus cyclosporine alone for
prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for
leukemia: long-term follow-up of a controlled trial. Blood 1989;73(6):1729-34.
13. Storb R, Deeg HJ, Pepe M, et al. Graft-versus-host disease prevention by methotrexate combined
with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe
aplastic anaemia: long-term follow-up of a controlled trial. Br J Haematol 1989;72(4):567-72.
14. Mrsić M, Labar B, Bogdanić V, et al. Combination of cyclosporin and methotrexate for
prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation for
leukemia. Bone Marrow Transplant 1990;6(2):137-41.
15. Chao NJ, Schmidt GM, Niland JC, et al. Cyclosporine, methotrexate, and prednisone compared
with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J
Med 1993;329(17):1225-30.
29
128 / 230
要望番号；IV-140
4.
Penack O, Marchetti M, Ruutu T, et al. Prophylaxis and management of graft versus host disease
after stem-cell transplantation for haematological malignancies: updated consensus
recommendations of the European Society for Blood and Marrow Transplantation. Lancet
Haematol 2020;7(2):e157-67.
5.
Penack O, Marchetti M, Aljurf M, et al. Prophylaxis and management of graft-versus-host
disease after stem-cell transplantation for haematological malignancies: updated consensus
recommendations of the European Society for Blood and Marrow Transplantation. Lancet
Haematol 2024;11(2):e147-59.
6.
Storb R, Deeg HJ, Thomas ED, et al. Marrow transplantation for chronic myelocytic leukemia:
a controlled trial of cyclosporine versus methotrexate for prophylaxis of graft-versus-host
disease. Blood 1985;66(3):698-702.
7.
Ringdén O, Bäckman L, Lönnqvist B, et al. A randomized trial comparing use of cyclosporin
and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients
with haematological malignancies. Bone Marrow Transplant 1986;1(1):41-51.
8.
Storb R, Deeg HJ, Farewell V, et al. Marrow transplantation for severe aplastic anemia:
methotrexate alone compared with a combination of methotrexate and cyclosporine for
prevention of acute graft-versus-host disease. Blood 1986;68(1):119-25.
9.
Storb R, Deeg HJ, Fisher L, et al. Cyclosporine v methotrexate for graft-v-host disease
prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled
trials. Blood 1988;71(2):293-8.
10. Bäckman L, Ringdén O, Tollemar J, et al. An increased risk of relapse in cyclosporin-treated
compared with methotrexate-treated patients: long-term follow-up of a randomized trial. Bone
Marrow Transplant 1988;3(5):463-71.
11. Sullivan KM, Storb R, Buckner CD, et al. Graft-versus-host disease as adoptive immunotherapy
in patients with advanced hematologic neoplasms. N Engl J Med 1989;320(13):828-34.
12. Storb R, Deeg HJ, Pepe M, et al. Methotrexate and cyclosporine versus cyclosporine alone for
prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for
leukemia: long-term follow-up of a controlled trial. Blood 1989;73(6):1729-34.
13. Storb R, Deeg HJ, Pepe M, et al. Graft-versus-host disease prevention by methotrexate combined
with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe
aplastic anaemia: long-term follow-up of a controlled trial. Br J Haematol 1989;72(4):567-72.
14. Mrsić M, Labar B, Bogdanić V, et al. Combination of cyclosporin and methotrexate for
prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation for
leukemia. Bone Marrow Transplant 1990;6(2):137-41.
15. Chao NJ, Schmidt GM, Niland JC, et al. Cyclosporine, methotrexate, and prednisone compared
with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J
Med 1993;329(17):1225-30.
29
128 / 230